Bionest Partners: New Transaction Advisory Success

Bionest acted for Marinomed in its out-licensing deal with Boehringer Ingelheim

PARIS & NEW YORK--(BUSINESS WIRE)-- Bionest Partners, a provider of advisory and management services to Life Sciences companies, announces today it had advised Austrian company Marinomed on anti-viral nasal spray licensing agreement with the international pharmaceutical group Boehringer Ingelheim.

This nasal spray is based on Marinomed’s anti-viral respiratory technology platform mavirex.

The deal signed between the two companies aims to further extend marketing of Marinomed’s anti-viral nasal spray for the treatment of the Common Cold to all of Europe (except Austria and UK), Russia and CIS, South Africa, parts of Asia and Australia.

Marinomed will receive an upfront payment in the million EUR range from Boehringer Ingelheim, in addition to payments upon the achievement of certain market entry milestones and royalties. Further Financial details were not disclosed.

Frédéric Desdouits, Managing Partners of Bionest Partners in charge of European biotechnologies and transactions said: “This deal on a medical device for the OTC market demonstrates our knowledge and capabilities in negotiating with great success sell-side mandates between a biotech company and major pharmaceutical groups like Boehringer Ingelheim. We are very proud of this result for Marinomed. This new success in the field of transaction advisory testifies the unique positioning and the excellence contribution of Bionest Partners’ teams.”

About Bionest Partners

Bionest Partners provides financial advisory and management services to help biotechnology, specialty pharmaceutical, large pharmaceutical companies; medical device companies and their shareholders maximize the value of their assets. The company, based in Paris with offices in New York and founded in 2003, has a broad customer base ranging from biotech start-ups to large and established companies. Bionest Partners has wide experience with more than 100 clients including Pfizer, Sanofi Aventis, GSK, Novartis, Biogen Idec, Bayer Schering Pharma, Millennium, Idenix, ProStrakan, Stallergenes, Innate Pharma, Genfit, Jubilant, Axa Private Equity, Blackstone, Candover. The company offers a hands-on approach and its areas of expertise include management consulting (strategy, organization, marketing, due diligence, surrogate management), corporate finance (private placement, IPO support, out-licensing, in-licensing, mergers and acquisitions), entry into Europe (assessment, strategy, go-it-alone/partnering, management support). Bionest has a strong and growing team of consultants as well as a network of associate members it can deploy to address specific client assignments.

For more information: www.bionest.com



CONTACT:

BIONEST PARTNERS :
Frédéric Desdouits – Managing Partner
Tél : 01 58 05 14 05
Email : [email protected]
or
MILESTONES – Press Relations :
Bruno ARABIAN – Jacques-Olivier COSTA
Phones: +33 (0) 1 75 44 87 40 / 42
E-mails: [email protected] / [email protected]

KEYWORDS:   Austria  United States  Europe  North America  France  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Medical Devices  Pharmaceutical  Research  Other Science  Diabetes  Medical Supplies  Science

MEDIA:

Logo
 Logo

Suggested Articles

Denali is partnering with Biogen on its Parkinson's disease program, netting a $560 million upfront fee and a $465 million investment.

In the first half of 2020, the regenerative medicine sector raised $10.7 billion, more than the total it raised in 2019.

The trial linked RG6346 to reductions in hepatitis B surface antigen that suggest the RNAi therapy can hold its own against drugs from J&J and Vir.